Skip to main content
Fig. 4 | Cancer & Metabolism

Fig. 4

From: ETV4/ALYREF-mediated glycolytic metabolism through PKM2 enhances resistance to ferroptosis and promotes the development of intrahepatic cholangiocarcinoma

Fig. 4

ALYREF stabilizes PKM2 mRNA through an m5C-dependent mechanism. (A) RIP assay revealed the binding between ALYREF and PKM2 in ICC cells. (B) The expression of ALYREF and PKM2 in ICC cells detected by RT-qPCR. (C) The expression of ALYREF and PKM2 in ICC cells detected by WB. (D) Following treatment with Actinomycin D, the degradation condition of PKM2 mRNA was detected. (E) The expression of NSUN2 in ICC cells analyzed by RT-qPCR. (F) The expression of NSUN2 in ICC cells examined by WB. (G) The enrichment level of PKM2 detected using m5C-RIP. *P < 0.05; **P < 0.01; ***P < 0.001; n = 3

Back to article page

Cancer & Metabolism

ISSN: 2049-3002